Previous 10 | Next 10 |
Curis share price has had dramatic fall since the FDA announced a hold on their “TakeAim” Leukemia study for Emavusertib on April 4, 2022, following the death of a patient. Recent price action since bottoming has been much more constructive and seems to show accumulation...
Curis Doses First Patient in Phase 1 Study of CA-4948 in Combination with Ibrutinib in Patients with Relapsed or Refractory Hematologic Malignancies - Amends existing protocol of ongoing Phase 1 study in R/R NHL - - Initial data expected in the fourth quarter of 2021 - P...
Curis Announces Initiation of Investigator-Sponsored Phase 2 LUCAS Study of CA-4948 for the Treatment of Anemia in Patients with Very Low, Low, or Intermediate-Risk Myelodysplastic Syndromes - Phase 2 study sponsored by investigators at Universität Leipzig in Germany - ...
Siebert Financial (SIEB) +453%.LM Funding America (LMFA) +101%.GameStop (GME) +75%.Koss Corporation (KOSS) +63%.Novavax (NVAX) +60% as its COVID-19 vaccine shows 89% efficacy in UK, 60% in South Africa.Catabasis Pharmaceuticals (CATB) +51% after announcing acquisition of Quellis Bio...
Quick overview of Curis and stock price history. Review on the potential for therapies that target the immune system checkpoint regulator “VISTA” (V-domain immunoglobulin (Ig) suppressor of T cell activation). Overview of CI-8993 including recent clinical results, po...
Curis to Present at B. Riley Securities Virtual Oncology Investor Conference PR Newswire LEXINGTON, Mass. , Jan. 14, 2021 /PRNewswire/ -- Curis, Inc. (NASDAQ: CRIS), a biotechnology company focused on the development of innovative therapeutics for the treatment o...
Looking For The Best Biotech Stocks To Watch This Week? 3 Names To Know Biotech stocks were some of the top performers on the stock market throughout 2020. With the coronavirus vaccine tailwind carrying over to 2021, investors still have their eyes peeled on the industry. Ri...
Curis to Present at H.C. Wainwright & Co. Bioconnect 2021 Virtual Conference Curis to Present at H.C. Wainwright & Co. Bioconnect 2021 Virtual Conference PR Newswire LEXINGTON, Mass. , Jan. 5, 2021 /PRNewswire/ -- Curis, Inc. (NASDAQ: CRIS), a bi...
Overview of Curis, including key partnerships, balance sheet, and recent stock price. Review of Non-Hodgkin’s Lymphoma, Myelodysplastic Syndromes and Acute Myeloid Leukemia. Patient need, current key therapies, and market size of some of the larger therapies in the space. O...
SOUTH SAN FRANCISCO, Calif., Dec. 22, 2020 (GLOBE NEWSWIRE) -- CytomX Therapeutics, Inc. (Nasdaq: CTMX), a clinical-stage oncology-focused biopharmaceutical company pioneering a novel class of investigational antibody therapeutics based on its Probody® technology platform, today announ...
News, Short Squeeze, Breakout and More Instantly...
2024-07-15 17:46:00 ET Stock Traders Daily has produced this trading report using a proprietary method. This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...
Curis to Present at Upcoming Healthcare Conference in July PR Newswire LEXINGTON, Mass. , July 10, 2024 /PRNewswire/ -- Curis, Inc. (NASDAQ: CRIS), a biotechnology company focused on the development of emavusertib (CA-4948), an orally available, small molecule IR...
2024-05-25 08:52:00 ET Stock Traders Daily has produced this trading report using a proprietary method. This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...